<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002187</url>
  </required_header>
  <id_info>
    <org_study_id>251D</org_study_id>
    <secondary_id>ISIS 2922-CS9</secondary_id>
    <nct_id>NCT00002187</nct_id>
  </id_info>
  <brief_title>A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis</brief_title>
  <official_title>A Randomized Comparison of Two Dosage Schedules of Intravitreal ISIS 2922 for Patients With Advanced Cytomegalovirus Retinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of two dosage schedules
      for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, randomized, open-label study comparing 2 dosage schedules
      of ISIS 2922.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fomivirsen sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Oral ganciclovir.

          -  Leukocyte growth factors (GM-CSF and G-CSF) for patients with febrile neutropenia.

        Patients must have:

          -  Documented AIDS.

          -  Clinical diagnosis of advanced CMV retinitis in 1 or both eyes.

          -  &gt;= 2 previous induction courses with anti-CMV retinitis therapy licensed by a
             regulatory agency.

          -  &gt; 25% retinal involvement with CMV retinitis.

          -  Baseline CMV retinitis lesions which have leading edges &gt; 1000 micrograms from the
             macula or optic disk.

        Prior Medication:

        Required:

          -  &gt;= 2 previous induction courses with anti-CMV retinitis therapy licensed by a
             regulatory agency.

        Allowed:

          -  All anti-CMV therapies other than ganciclovir must be discontinued no less than 2 days
             prior to entry.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms and conditions are excluded:

          -  External ocular infection in the eye to be treated.

          -  Other herpetic infections of the retina, toxoplasma, retinochoroiditis, or other
             disease of the fundus that would preclude assessment of CMV retinitis in the eye to be
             treated.

          -  Ocular conditions that will obstruct visualization of the posterior ocular structures
             on the eye to be treated.

          -  Retinal detachment in the eye to be treated.

          -  Ganciclovir implant in the eye to be treated.

          -  Known or suspected allergy to phosphorothioate oligonucleotides or intolerance of ISIS
             2922.

          -  Silicone oil in the eye to be treated.

          -  Pseudoretinitis pigmentosa.

          -  Syphilis.

        Patients with the following prior conditions are excluded:

          -  History of surgery to correct retinal detachment in the eye to be treated.

          -  History of syphilis.

             1. Systemic anti-CMV therapies other than oral ganciclovir.

          -  Mellaril, Stelazine, chlorpromazine and clofazimine.

          -  Combination use of ethambutol and fluconazole.

          -  Investigational medications and/or procedures for the treatment of CMV retinitis in
             the eye to be treated.

          -  Ganciclovir implant delivery device in the eye to be treated.

          -  Ganciclovir other than oral.

          -  Foscarnet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Retina - Vitreous Associates Med Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Eye Med Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>911052536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California San Francisco / SF Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Jacob Lalezari</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Alan Palestine</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Julio Perez</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Retina</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Ctr for Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ Med Ctr</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreo - Retinal Consultants</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose &amp; Throat Association</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hahnemann Univ Hosp</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>191021192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novum Inc</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>New CMV drug won't replace other therapies. AIDS Alert. 1998 Nov;13(11):124-6.</citation>
    <PMID>11365968</PMID>
  </reference>
  <reference>
    <citation>Roehr B. Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care. 1998 Oct;4(10):14-6.</citation>
    <PMID>11365956</PMID>
  </reference>
  <verification_date>December 1998</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Drug Administration Schedule</keyword>
  <keyword>Cytomegalovirus Retinitis</keyword>
  <keyword>fomivirsen</keyword>
  <keyword>Vitreous Body</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fomivirsen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

